Basic Information
Trecondi
Regulatory Information
EMEA/H/C/004751
June 20, 2019
5
February 21, 2024
Company Information
Germany
Theaterstrasse 6 22880 Wedel
medac Gesellschaft für klinische Spezialpräparate mbH
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.
Overview Summary
Trecondi is a medicine given to patients before they have a bone marrow transplant from a donor known as ‘allogeneic haematopoietic stem cell transplantation’. It is used as a ‘conditioning’ treatment to clear the patient’s bone marrow and make room for the transplanted bone marrow cells, which can then produce healthy blood cells. Trecondi is used together with a medicine called fludarabine in adults and children from 1 month of age with blood cancers or other severe disorders requiring a bone marrow transplant. The active substance in Trecondi is treosulfan. Haematopoietic stem cell transplantation is rare, and Trecondi was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 23 February 2004.